VIIV HEALTHCARE PTY LTD

πŸ‡¦πŸ‡ΊAustralia
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults

First Posted Date
2015-03-11
Last Posted Date
2018-08-20
Lead Sponsor
ViiV Healthcare
Target Recruit Count
86
Registration Number
NCT02386098
Locations
πŸ‡ΉπŸ‡­

GSK Investigational Site, Bangkok, Thailand

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

First Posted Date
2015-02-27
Last Posted Date
2016-06-27
Lead Sponsor
ViiV Healthcare
Target Recruit Count
63
Registration Number
NCT02373930
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, Overland Park, Kansas, United States

Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

Phase 3
Active, not recruiting
Conditions
HIV Infections
Interventions
Drug: BMS-663068
Other: Placebo
First Posted Date
2015-02-13
Last Posted Date
2024-07-23
Lead Sponsor
ViiV Healthcare
Target Recruit Count
371
Registration Number
NCT02362503
Locations
πŸ‡¬πŸ‡§

GSK Investigational Site, London, United Kingdom

A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers

Phase 1
Completed
Conditions
HIV Infections
Interventions
Drug: GSK1265744 30mg
First Posted Date
2015-02-03
Last Posted Date
2020-08-05
Lead Sponsor
ViiV Healthcare
Target Recruit Count
16
Registration Number
NCT02354950
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, Minneapolis, Minnesota, United States

Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment

First Posted Date
2015-02-03
Last Posted Date
2020-08-28
Lead Sponsor
ViiV Healthcare
Target Recruit Count
16
Registration Number
NCT02354937
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, Minneapolis, Minnesota, United States

Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir

First Posted Date
2015-01-26
Last Posted Date
2015-07-13
Lead Sponsor
ViiV Healthcare
Target Recruit Count
37
Registration Number
NCT02345707
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, Overland Park, Kansas, United States

Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany

First Posted Date
2015-01-21
Last Posted Date
2019-02-11
Lead Sponsor
ViiV Healthcare
Target Recruit Count
403
Registration Number
NCT02342769
Locations
πŸ‡©πŸ‡ͺ

GSK Investigational Site, Weimar, Germany

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

First Posted Date
2014-10-29
Last Posted Date
2018-01-24
Lead Sponsor
ViiV Healthcare
Target Recruit Count
32
Registration Number
NCT02277600
Locations
πŸ‡ΊπŸ‡Έ

GSK Investigational Site, San Antonio, Texas, United States

Food Effect Study With BMS-955176

Phase 1
Completed
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Drug: BMS-955176
First Posted Date
2014-10-24
Last Posted Date
2017-04-17
Lead Sponsor
ViiV Healthcare
Target Recruit Count
12
Registration Number
NCT02273947
Locations
πŸ‡¬πŸ‡§

GSK Investigational Site, Ruddington Fields, Nottinghamshire, United Kingdom

Study on Pharmacokinetics

Phase 1
Completed
Conditions
HIV Infections
Interventions
Drug: Rosuvastatin
Drug: BMS-663068
First Posted Date
2014-09-09
Last Posted Date
2018-04-17
Lead Sponsor
ViiV Healthcare
Target Recruit Count
50
Registration Number
NCT02234882
Β© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy